Biologic cancer treatments have become incredibly important in oncology, but they can be expensive. Biosimilars are molecules manufactured to replicate the effects of biologics. They give patients and providers a choice and help to drive prices down through competition, but doctors, patients and caregivers need to understand what biosimilars are, what they can do, and the strengths and limits of this new frontier in medicine.
Year: 2017
Watch our webinar titled “Cancer Associated Blood Clots”
This webinar introduces you to the effects of blood clots on cancer patients. This webinar also provides you with the following information: How and why blood clots effect cancer patients more than the general population Diagnosis and treatment options Resources for more information The presentation is followed by an interactive discussion with participants. Presenter Information Dr. Peter L. Gross obtained his MSc in Biochemistry and his
Avelumab Survey
The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of Avelumab for the treatment of patients with Merkel cell carcinoma. The survey will be open until Oct. 20. The results of our survey are to be submitted in our patient evidence study to the pan-Canadian Oncology Drug Review (pCODR) on Oct. 24, 2017. To complete
Have you experienced a blood clot during cancer treatment?
If you or a loved one has experienced a blood clot after you were diagnosed with cancer or during chemotherapy, you live in Ontario and would like to help CCSN raise awareness about it, please get in touch with CCSN president & CEO Jackie Manthorne at jmanthorne@survivornet.ca. Every year there are 30,000 incidences of cancer-associated thrombosis in Canada, with approximately 20 to 25 percent of
Cancer Patients Celebrate New Program for Take-Home Cancer Medications in Nova Scotia
Halifax, Nova Scotia, September 27, 2017 – The CanCertainty Coalition, the united voice of 35 Canadian cancer organizations, applauds the McNeil Government’s decision to address the funding gap for take-home cancer medications and eliminate much of the financial hardship and related stress that patients in the province face, as announced in Tuesday’s budget. “This is a major breakthrough for patients and their families across the
Watch our webinar titled “How Changes to the Patented Medicine Prices Review Board Could Affect Patients’ Access to Drugs”
This webinar introduces you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients. This webinar also provides you with the following information: Summary, analysis and next steps regarding proposed price regulation changes Patient perspectives on the proposed reforms Discussion on potential impact, issues and opportunities from these proposed changes How patients